Top

Notification of interruption to supply

20 March 2017

RANZCOG has been notified by Pfizer that due to manufacturing issues, the current stock of PROSTIN® E2 VAGINAL GEL 2mg is expected to be depleted by the end of March 2017, and availability of new stock is not expected until May 2017. There is no safety concern with this medicine.
 
Vaginal dinoprostone is available from another manufacturer.
 
Full Product Information for PROSTIN® E2 VAGINAL GEL can be accessed at www.pfizer.com.au
 
For any medical enquiries regarding PROSTIN® E2 VAGINAL, contact Pfizer Medical Information on 1800 675 229.
 
As RANZCOG recognises the potential impact this may have on your practice, to hospital departments across Australia, and to the women in your care, we are endeavouring to ensure all members are made aware of this important issue through multiple communication channels.


 



MEDIA CENTRE

News

Dr Pieter Mourik (AM)

Being recognised in the Australia Day honours was a highlight for this rural medicine advocate.
 

20/09/2021

News

RANZCOG urges all practitioners to help pregnant women get vaccinated

RANZCOG urges all practitioners to heed the advice issued by RANZCOG and ATAGI which recommends that pregnant women are routinely offered Pfizer or Moderna mRNA vaccine at any stage of pregnancy.

17/09/2021

News

EOI: eLearning content reviewers

As women’s healthcare evolves rapidly, RANZCOG is keen to ensure its eLearning programs and modules meet member expectations and education standards.

13/09/2021